Stocks · SYMBIOTEC

Symbiotec Pharmalab delivery percentage & share price.

· data for the trading session of Wed 18 Nov 2026

Last close · 18 Nov 2026
₹1,621.30 +1.29%
NSE: SYMBIOTEC
⚠ Under NSE surveillance: Short-term ASM Stage I
1W+5.4%1M+30.9%
52-week range
₹934.20-2.6% from the high₹1,664.90

Price, volume and delivery

Candles adjusted for splits and bonuses. In the lower panel, the grey bar is the day’s volume and the coloured bar is the part that was delivered; bright green marks big-buyer days (delivered shares 3× the stock’s normal or more, with a normal-or-higher delivery %).

Symbiotec Pharmalab share price today: what happened on 18 November

Written from NSE’s end-of-day data for 18 Nov 2026. Updated every trading evening. Facts, not advice.

Symbiotec Pharmalab rose to ₹1,621.30 on Wednesday, 18 November 2026, up ₹20.70 or 1.29% from the previous close of ₹1,600.60. It opened at ₹1,600.60 and traded between ₹1,585.30 and ₹1,650.00, a range of 4.0% of its price, and finished in the middle of it.

This was its 2nd gain in a row. It closed higher on 6 of the last 10 sessions and is +31.5% over that stretch. Looking further back: one week +5.4%, one month +30.9%.

3.12 lakh shares changed hands, worth about ₹50.6 crore, 0.3 times the 20-session average, a quieter day than usual. Of those, 35% (1.09 lakh shares) were taken for delivery, meaning they actually changed owners instead of being traded within the day. That compares with a 60-session average of 32%. There were no big-buyer days (delivery several times above normal) in the last three months.

The close is 31.1% above the 50-day average of ₹1,236.71. The 14-day RSI, a 0–100 gauge of recent momentum, reads 70, in the neutral zone between 30 and 70. It sits 2.6% below its 52-week high of ₹1,664.90 and 73.5% above the low of ₹934.20, in the upper part of the year’s range.

Looking at where shares were actually delivered over the past year, the busiest price zone below today’s close is around ₹1,245 (-23.4%). Prices often slow down near such zones because many holders bought there, but they are history, not predictions.

NSE has it under surveillance (Short-term ASM Stage I), which can mean tighter trading rules.

On a typical day Symbiotec Pharmalab moves about ±4.2%, and its average session spans 5.8% from high to low. It closed higher on 47% of the sessions since listing (54 sessions). It opened with a gap of 1% or more 10 times in that time (6 up, 4 down). Its best day since listing was 6 November 2026 (+19.04%) and its worst was 23 September 2026 (-5.25%).

Last five sessions

DayCloseChangeVolumeDelivery
Wed 18 Nov₹1,621.30+1.29%3.12 lakh35%
Tue 17 Nov₹1,600.60+1.72%1.67 lakh35%
Mon 16 Nov₹1,573.50-2.35%3.44 lakh39%
Fri 13 Nov₹1,611.30-1.89%2.72 lakh28%
Thu 12 Nov₹1,642.40+6.75%10.33 lakh30%

Price levels by delivered volume

Where the most Symbiotec Pharmalab shares were actually delivered over the last year. Each day’s delivered shares are spread across that day’s high–low range; the peaks are the busiest price zones. Below the close: support zones; above: resistance zones. History, not a forecast.

₹1,621₹1,243₹1,164₹1,107
  • Last close₹1,621.3018 Nov
  • Support 1₹1,245-23.4% · 5.3% of the year’s delivery
  • Support 2₹1,165-28.2% · 9.3% of the year’s delivery
  • Support 3₹1,105-31.7% · 11.1% of the year’s delivery

Symbiotec Pharmalab IPO

How the Symbiotec Pharmalab IPO listed and what the share did after. Full IPO page: subscription, listing day and returns after listing →

Issue price₹988.00listed 1 Sep 2026
Subscribed71.3×times, all investors
Listing gain+0.0%at the opening price
Since the IPO+64.1%to the last close

Its listing gain beat 21% of the 227 main-board IPOs since Oct 2024. How IPOs usually do after listing →

Symbiotec Pharmalab at a glance

  • Symbiotec Pharmalab closed at ₹1,621.30 on 18 Nov 2026 (+1.29% on the day).
  • It trades 2.6% below its 52-week high of ₹1,664.90 and 73.5% above its low of ₹934.20.
  • 35% of the shares traded on 18 Nov were delivered, against a 60-session average of 32%.
  • There were no big-buyer days (delivery far above normal) in the last three months.
  • A typical day moves it about ±4.2%: calmer than 100% of the 1,443 most traded NSE stocks.

Symbiotec Pharmalab pros and cons

Written automatically from the latest results, shareholding, valuation against its sector, and price and delivery data. Facts, not advice.

Pros

  • Mutual funds raised their stake by 6.6 points last quarter, to 12.2%.
  • Trading at or near its 52-week high.

Cons

  • Foreign investors (FIIs) cut their stake by 17.3 points last quarter, to 3.8%.

Symbiotec Pharmalab fundamentals

Quarterly results and shareholding from NSE filings. Profit is the share owed to the company’s own shareholders. Compare in the stock screener →

Market cap₹10,417 Crshares × last price
Revenue₹280 CrQ2 FY27
Net profit₹52 CrQ2 FY27

Revenue

₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.

Q1 FY27: ₹218 Cr218Q1 FY27Q2 FY27: ₹280 Cr280Q2 FY27

Net profit

₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.

Q1 FY27: ₹14 Cr14Q1 FY27Q2 FY27: ₹52 Cr52Q2 FY27

Who owns Symbiotec Pharmalab

Shareholding pattern for the quarter to 30 Sep 2026, from the company’s filing with NSE.

Promoters 33.3%Foreign investors (FII/FPI) 3.8%Mutual funds 12.2%Insurance companies 1.1%Other domestic institutions 19.9%Retail investors 7.8%Others 21.9%

Change since Aug 2026:

Foreign investors-17.29 ptsMutual funds+6.64 ptsOther domestic institutions-0.99 ptsRetail investors-8.79 pts

Symbiotec Pharmalab balance sheet, returns and cash flow

From the consolidated half-year and annual results filed with NSE (latest: 30 Sep 2026), on the same basis as the quarterly figures above.

ROE–profit ÷ shareholders’ equity, last 4 quarters
ROCE–operating profit ÷ capital employed
Debt / equity0.24borrowings (excl. leases) ÷ equity
Book value / share₹211.82P/B 7.7
Interest cover–operating profit ÷ interest
Sep 2026half year
Shareholders’ equity₹1,361 Cr
Borrowings (excl. leases)₹333 Cr
Cash, bank balances & current investments₹21.8 Cr
Operating cash flow₹45.9 Cr
Capex (PPE + intangibles)₹114 Cr

Balance sheet items are as at the date shown; cash flows cover the half year or full year to that date. ₹ crore.

Delivery and big-buyer days

Delivered shares change owners for real; intraday trades don’t. Days when delivery jumps far above normal often mean large investors were buying or selling.

Delivery, last session35%1.09 L shares
Average, 60 sessions32%1-year median 33%
Big-buyer days, 1 year0delivery 3× normal or more

Delivery calendar, last 12 months

Each square is a session. The brighter the green, the more shares were delivered compared with Symbiotec Pharmalab’s normal. Hover or tap a square for the day.

Hover a square
QuietBelow normalNormalHighBig-buyer day

Symbiotec Pharmalab timeline

Everything that happened to Symbiotec Pharmalab, newest first: deals, promoter filings, results, big-buyer days, new highs and big moves.

  • November 2026
  • 6 Nov
    Jumped 19.0% in one sessionClosed at ₹1,513.60, about 4.6× a normal day’s move.

My notes on Symbiotec Pharmalab

Private: saved only in this browser, never sent to us.

Questions

What is the 52-week high and low of Symbiotec Pharmalab?
Over the last 52 weeks, Symbiotec Pharmalab (SYMBIOTEC) traded between ₹934.20 and ₹1,664.90 (adjusted for splits and bonuses). The last close of ₹1,621.30 on 18 Nov 2026 is 2.6% below the high.
What is the delivery percentage of Symbiotec Pharmalab?
On 18 Nov 2026, 35.1% of Symbiotec Pharmalab’s traded shares were delivered. The 60-session average is 32.2%, and its median over the last year is 32.6%.
How volatile is Symbiotec Pharmalab?
Not enough history yet.
What is the market cap of Symbiotec Pharmalab?
About ₹10,417 Cr, from 64,250,000 shares at the last close.
Who owns Symbiotec Pharmalab? What is its shareholding pattern?
As of 30 Sep 2026: promoters 33.28%, foreign investors 3.79%, mutual funds 12.18%, insurance companies 1.07% and retail investors 7.81%.
Is Symbiotec Pharmalab debt free?
No. Borrowings (excluding lease liabilities) were 0.24× equity as at 30 Sep 2026.
What is the book value of Symbiotec Pharmalab?
₹211.82 per share (consolidated shareholders’ equity as at 30 Sep 2026 divided by shares outstanding), a price-to-book of 7.7.
What are the support and resistance levels of Symbiotec Pharmalab?
Over the last year, the most Symbiotec Pharmalab shares were delivered around ₹1,245 below the current price (last close ₹1,621.30 on 18 Nov 2026). These busy zones often act as support and resistance, but they describe the past, not the future.
What was the IPO price of Symbiotec Pharmalab?
Symbiotec Pharmalab came to the market at ₹988.00 a share (price band ₹938 to ₹988) and listed on 1 September 2026, opening +0.0% against the issue price. At the last close it is +64.1% from the IPO price.

Data from NSE’s daily files, adjusted for splits and bonuses. Past behaviour is not a forecast. This is information, not investment advice; ChartMine is not a SEBI-registered adviser.

See it live on your chart.ChartMine for TradingView.